Tysabri Unión Europea - español - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - esclerosis múltiple - inmunosupresores selectivos - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Fingolimod Mylan Unión Europea - español - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod clorhidrato de - la esclerosis múltiple remitente-recurrente - inmunosupresores - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 y 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Tyruko Unión Europea - español - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - inmunosupresores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 y 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

CLARISCAN 0,5 MMOL/ML SOLUCION INYECTABLE EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

clariscan 0,5 mmol/ml solucion inyectable efg

ge healthcare bio-sciences, s.a.u. - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml inyectable 50 ml - gadoterico acido 0,5 mmol - Ácido gadotérico

CLARISCAN 0,5 MMOL/ML SOLUCION INYECTABLE EN JERINGA PRECARGADA EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

clariscan 0,5 mmol/ml solucion inyectable en jeringa precargada efg

ge healthcare bio-sciences, s.a.u. - gadoterico acido - soluciÓn inyectable en jeringa precargada - 0,5 mmol/ml inyectable 20 ml - gadoterico acido 0,5 mmol - Ácido gadotérico

DOTAREM 0,5 mmol/ml SOLUCION INYECTABLE EN JERINGA PRECARGADA España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

dotarem 0,5 mmol/ml solucion inyectable en jeringa precargada

guerbet - gadoterico acido - soluciÓn inyectable en jeringa precargada - 0,5 mmol/ml inyectable 20 ml - gadoterico acido 0,5 mmol - Ácido gadotérico

DOTAREM 0,5 mmol/ml SOLUCION INYECTABLE EN VIAL España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

dotarem 0,5 mmol/ml solucion inyectable en vial

guerbet - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml - gadoterico acido 0,5 mmol - Ácido gadotérico

CYCLOLUX 0,5 MMOL/ML SOLUCION INYECTABLE EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

cyclolux 0,5 mmol/ml solucion inyectable efg

sanochemia pharmazeutika gmbh - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml inyectable 10 ml - gadoterico acido 0,5 mmol - Ácido gadotérico

CYCLOLUX REP 0,5 MMOL/ML SOLUCION INYECTABLE EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

cyclolux rep 0,5 mmol/ml solucion inyectable efg

sanochemia pharmazeutika gmbh - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml inyectable 10 ml - gadoterico acido 0,5 mmol - Ácido gadotérico

DOTAGRAF 0,5 MMOL/ML SOLUCION INYECTABLE UNIDOSIS EFG España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

dotagraf 0,5 mmol/ml solucion inyectable unidosis efg

bayer hispania s.l. - gadoterico acido - soluciÓn inyectable - 0,5 mmol/ml - gadoterico acido 0,5 mmol - Ácido gadotérico